

To Whom It May Concern:

Company Name: Taisho Pharmaceutical Holdings Co., Ltd  
 Head Office: 3-24-1, Takada, Toshima-ku, Tokyo  
 Representative: Akira Uehara, Chief Executive Officer  
 (First Section of TSE: Code 4581)  
 Contact: Takashi Shibata, General Manager  
 Corporate Communications  
 (Tel:+81-3985-1115)

Notice of Change in Status of Major Shareholder

Taisho Pharmaceutical Holdings Co., Ltd. (“the Company”) has announced a following change in the status of a major shareholder of the Company in November 29, 2016.

1. Background to the Change in Status of Major Shareholder

Shoji Uehara, Emeritus Chairman of the Company and one of the Company’s major shareholders, has announced his intent to contribute 2,100,000 shares of the Company’s common shares he holds to the Uehara Memorial Foundation, where he has served as Second President. This resulted in a change in the status of a major shareholder of the Company.

2. Outline of the Change in Status of Major Shareholder

(1) Name	Shoji Uehara
(2) Address	Shinjuku, Tokyo
(3) Relationship with the Company	Emeritus Chairman

3. Number of voting rights held by the relevant shareholder before and after the change (shareholding), and the percentage of the total number of voting rights of all shareholders

	Number of voting rights (Shareholding)	Percentage of the total number of voting rights of all shareholders*	Major shareholder ranking
Before change (As of September 30, 2016)	99,743 (9,974,380 shares)	12.56%	2nd
After change	78,743 (7,874,380 shares)	9.92%	2nd

\* The number of the shares subtracted from the issued share total number as the shares that do not have a voting right: 10,734,953 shares

The total number of shares issued as of September 30, 2016: 90,139,653 shares

4. Outlook

This change in the status of major shareholder will have no impact on the Company’s business performance.

5. (Reference)

Overview of the Uehara Memorial Foundation

(1) Name	The Uehara Memorial Foundation
(2) Address	3-26-3 Takada, Toshima-ku, Tokyo, Japan
(3) Representative	President Akira Uehara (Chief Executive Officer of the Company)
(4) Establishment	Established on February 19, 1985 based on approval of the Ministry of Health, Labour and Welfare Became a public interest incorporated foundation on February 1, 2010
(5) Description of activities	(1) In fields related to life science: a) Provision of grants for research b) Conferral of awards for research accomplishments c) Dispatch and invitation of researchers and provision of grants thereto d) Holding research meetings, lectures and symposiums and providing grants for these events e) Publication of research accomplishments and grants for such research (2) Other activities necessary to achieving the objectives of the Foundation